ADVISORY, March 11, 2013 (GLOBE NEWSWIRE) -- What: KaloBios Pharmaceuticals, Inc. [KBIO], a biopharmaceutical company dedicated to improving the lives of seriously ill patients with difficult-to-treat diseases through a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs), will visit the NASDAQ MarketSite in Times Square. In honor of the occasion, David Pritchard, President & CEO, will ring the Closing Bell. Where: NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio When: Tuesday, March 12, 2013 – 3:45 p.m. to 4:00 p.m. ET Contact : Joan E. Kureczka Kureczka/Martin Associates Tel: (415) 821-2413 Mobile: (415) 690-0210 Joan@Kureczka-Martin.com Consuelo Alatorre KaloBios Pharmaceuticals, Inc. Tel: (650) 243-3120 Mobile: (650) 278-6805 email@example.com NASDAQ MarketSite: Jen Knapp (212) 401-8916 Jennifer.firstname.lastname@example.org Feed Information: Fiber Line (Encompass Waterfront): 4463
|Gal 3C/06C 95.05 degrees West|
|18 mhz Lower|
|DL 3811 Vertical|
Currently, KaloBios has three drug development programs:
- KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases, is being developed for the treatment of severe asthma and is currently enrolling patients in a 150 patient Phase 2 study in the United States, Europe and Australia.
- KB001-A, an anti-PcrV mAb fragment, is partnered exclusively with Sanofi Pasteur and is being developed for the prevention and treatment of Pseudomonas aeruginosa (Pa) infection. KaloBios has retained rights for the cystic fibrosis (CF) indication and has initiated a 180 patient Phase 2 study in CF subjects with chronic Pa infection in the United States. Sanofi is pursuing a ventilator associated pneumonia prevention indication in the intensive care setting.
- KB004, an anti-EphA3 mAb, has potential in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in subjects with hematologic malignancies.